W
ALXN

WealthStone’s Alexion Pharmaceuticals ALXN Stock Holding History

WealthStone’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$245K Buy
1,608
+67
+4% +$10.4K 0.09% 206
2020
Q4 		$241K Buy
+1,541
New +$198K 0.09% 175
2020
Q3 		– Sell
-1,998
Closed -$224K – 256
2020
Q2 		$224K Buy
+1,998
New +$212K 0.11% 139
2019
Q3 		– Sell
-8
Closed -$1.05K – 661
2019
Q2 		$1.05K Buy
+8
New +$1.03K ﹤0.01% 667

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WealthStone's ALXN Position: Q1 2021 in Review

WealthStone increased its Alexion Pharmaceuticals (ALXN) stake by 4.3% in Q1 2021, buying an estimated $10.4K and bringing the position to 1,608 shares worth $245K. The position accounts for 0.09% of the portfolio, ranked #206.

WealthStone first reported a position in ALXN in Q2 2019 and has held it in 4 quarters since. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • WealthStone held 1,608 shares of Alexion Pharmaceuticals worth $245K as of Q1 2021.
  • WealthStone bought 67 Alexion Pharmaceuticals shares in Q1 2021, an estimated $10.4K.
  • Alexion Pharmaceuticals made up 0.09% of WealthStone's portfolio in Q1 2021, its #206 holding.
  • WealthStone first reported a position in Alexion Pharmaceuticals in Q2 2019 and has held it in 4 quarters since.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on WealthStone's 13F filing for Q1 2021, filed 13 May 2021.